Stablecoin Development Earnings Call Transcripts
Fiscal Year 2026
-
Six proposals were presented and approved, including major share issuances, amendments to the certificate of incorporation, and a new equity incentive plan. Quorum was established with over 96% voting power represented, and the meeting concluded with a Q&A session.
Fiscal Year 2024
-
The meeting focused on two major proposals: selling Avenova and dissolving the company. Due to insufficient votes, both proposals were adjourned for further solicitation, with the meeting set to reconvene on January 16th, 2025.
-
Eye care sales grew in Q2 2024, with improved gross margins and reduced marketing spend, driven by recurring online revenue and a loyal customer base. Strategic partnerships and a recent capital raise position the business for further growth in the expanding U.S. dry eye market.